The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile ...

"At the end of the week, you will be an entirely different person," the trailer for Season 3 of "The White Lotus" begins. The trailer, which debuted on Jan. 27, shows groups of guests drinking ...

Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on developing treatments for rare diseases, has significantly outpaced both its biotechnology peers and the S&P 500 since early 2022.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Add a description, image, and links to the svg-preview topic page so that developers can more easily learn about it.

Vertex Pharmaceuticals Inc. (NASDAQ ... This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...

EXCLUSIVE: The long-awaited film adaptation of Erik Larson’s bestselling book The Devil in the White City just got a shot of adrenaline, as sources tell Deadline that 20th Century has come on to ...